SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

DDD85646

Item No. 13839



CAS Registry No.:	1215010-55-1
Formal Name:	2,6-dichloro-4-[2-(1-piperazinyl)-4-pyridinyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide
Synonym:	IMP-366
MF:	$C_{21}H_{24}Cl_2N_6O_2S$
FW:	495.4
Purity:	≥95%
UV/Vis.:	λ_{max}: 226, 258 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

DDD85646 is supplied as a crystalline solid. A stock solution may be made by dissolving the DDD85646 in the solvent of choice. DDD85646 is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of DDD85646 in these solvents is approximately 25 mg/ml. DDD85646 is also slightly soluble in ethanol.

DDD85646 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, DDD85646 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. DDD85646 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

DDD85646 is a moderately bioavailable pyrazole sulphonamide inhibitor of *T. brucei* N-myristoyltransferase (T*b*NMT) with an apparent K_i value of 1.44 nM.[1] *T. brucei* is the parasite responsible for human African trypanosomiasis (HAT), also known as African sleeping sickness, and is transmitted through the tsetse fly. DDD85646 administration in mice (12.5 mg/kg for four days) ameliorated *T. brucei* in an acute mouse model of HAT.[1] It less potently inhibits growth of *T. cruzi* (EC_{50} = 6.9 µM).

Reference

1. Frearson, J.A., Brand, S., McElroy, S.P., *et al.* N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. *Nature* **464(7829)**, 728-732 (2010).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM